ClinicalTrials.gg
CompletedNCT02989922Updated Mar 15, 2024Results posted

A Study to Evaluate SHR-1210 in Subjects With Advanced HCC

A Phase 2 interventional study of SHR-1210 in Hepatocellular Carcinoma Non-Resectable, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 17 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing camrelizumab in Carcinoma, Hepatocellular — 19 open to participants now, 24 under way, 8 of them phase 3. camrelizumab · Carcinoma, Hepatocellular.

Enrollment
6th of 44
220 · median 51
Started
2016
with 1 other
Phase 2
24 of 44
9 open now
Registered
2nd of 44
by date
Lead sponsor
5 of 44
Jiangsu HengRui Medicine Co., Ltd.

Among the 44 studies testing camrelizumab in Carcinoma, Hepatocellular, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 24 in phase 2, and was the 2nd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

19 of the 44 studies testing camrelizumab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing camrelizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This a randomized controlled Phase 2/3 study to evaluate the efficacy and safety of SHR-1210 in subjects with advanced HCC who failed or intolerable to prior systemic treatment. The primary study hypothesis is that SHR-1210 treatment improves Objective Response Rate and Overall Survival when compare with SOC.

Read the detailed description

In June 2017, this study was revised to expand the Phase 2 part to enroll more subjects and remove the Phase 3 part under the same protocol. A Phase 3 study will be initiated separately.

03

Conditions studied

  • Hepatocellular Carcinoma Non-Resectable
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed HCC in advanced stage; not suitable to surgery or local regional treatment; with at least one per 1.1
  2. Failed or intolerable to at least one prior systemic treatment for advanced HCC
  3. Performance Status of 0 or1
  4. Class A or B with 7 points
  5. of at least 12 weeks
  6. \<500 IU/ml
  7. Adequate organ function
  8. Male or female participants of must be willing to use an adequate method of starting with the first dose of study drug through 60 days for female subjects and 120 days for male subjects after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  2. Known liver transplant or plan to transplant
  3. GI hemorrhage with 6 months
  4. History or current
  5. Active known, or suspected disease
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    SHR-1210 Q2W

    Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks

    Biological: SHR-1210

  • Experimental
    SHR-1210 Q3W

    Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 3 weeks

    Biological: SHR-1210

Interventions

  • BiologicalSHR-1210

    SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Tumour responses were evaluated by the independent review committee (IRC) according to RECIST 1.1.The primary endpoints were the proportion of patients with a IRC-assessed objective response (defined as the percentage of patients whose best overall response was confirmed complete or partial response).

    Time frame: approximate 3 years

  2. 6-month Overall Survival Rate

    6-month overall survival rate (defined as cumulative overall survival rate from the date of the first dose to 6 months)

    Time frame: from the date of the first dose to 6 months

Secondary outcomes

  1. Duration of Response

    time from first response to progression or death base on the IRC assessment

    Time frame: approximate 3 years

  2. Adverse Events

    Number of Subjects with one or more adverse events as assessed by CTCAE 4.03

    Time frame: approximate 3 years

  3. Overall Survival

    Time from first dose to death from any cause

    Time frame: approximate 3 years

07

Results

Posted Mar 15, 2024

Participant flow

Participant flow — Overall Study
MilestoneSHR-1210 Q2WSHR-1210 Q3W
Started111109
Treated109108
Completed7281
Not completed3928

Outcome measures

PrimaryObjective Response Rate

Tumour responses were evaluated by the independent review committee (IRC) according to RECIST 1.1.The primary endpoints were the proportion of patients with a IRC-assessed objective response (defined as the percentage of patients whose best overall response was confirmed complete or partial response).

Time frame:
approximate 3 years
Reported as:
Number · percentage of participants
Objective Response Rate
percentage of participantsSHR-1210 Q2WSHR-1210 Q3W
Objective Response Rate11.9 (6.5 to 19.5)16.7 (10.2 to 25.1)
Primary6-month Overall Survival Rate

6-month overall survival rate (defined as cumulative overall survival rate from the date of the first dose to 6 months)

Time frame:
from the date of the first dose to 6 months
Reported as:
Number · percentage of participants
6-month Overall Survival Rate
percentage of participantsSHR-1210 Q2WSHR-1210 Q3W
6-month Overall Survival Rate75.9 (66.6 to 82.9)73.0 (63.6 to 80.4)
SecondaryDuration of Response

time from first response to progression or death base on the IRC assessment

Time frame:
approximate 3 years
Reported as:
Median · months
Duration of Response
monthsSHR-1210 Q2WSHR-1210 Q3W
Duration of Response30.4 (2.8 to NA)30.5 (5.4 to NA)
SecondaryAdverse Events

Number of Subjects with one or more adverse events as assessed by CTCAE 4.03

Time frame:
approximate 3 years
Reported as:
Number · participants
Adverse Events
participantsSHR-1210 Q2WSHR-1210 Q3W
Adverse Events109108
SecondaryOverall Survival

Time from first dose to death from any cause

Time frame:
approximate 3 years
Reported as:
Median · months
Overall Survival
monthsSHR-1210 Q2WSHR-1210 Q3W
Overall Survival14.3 (11.5 to 19.5)13.2 (9.4 to 16.3)

Adverse events

Collected over approximate 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SHR-1210 Q2W27/109 (24.8%)50/109 (45.9%)108/109 (99.1%)
SHR-1210 Q3W29/108 (26.9%)46/108 (42.6%)107/108 (99.1%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventSHR-1210 Q2WSHR-1210 Q3W
Disease progressionGeneral disorders13/1099/108
Hepatic function abnormalHepatobiliary disorders2/1096/108
Hepatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1094/108
Upper gastrointestinal haemorrhageGastrointestinal disorders2/1094/108
Hepatic failureHepatobiliary disorders4/1093/108
Multiple organ dysfunction syndromeGeneral disorders3/1093/108
Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1092/108
Aspartate aminotransferase increasedInvestigations3/1090/108
DeathGeneral disorders0/1092/108
Intracranial tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1092/108
Most frequent other events
Showing 10 of 58
Most frequent other events
EventSHR-1210 Q2WSHR-1210 Q3W
Haemangioma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)69/10976/108
Aspartate aminotransferase increasedInvestigations52/10948/108
Alanine aminotransferase increasedInvestigations47/10946/108
Blood bilirubin increasedInvestigations40/10938/108
Platelet count decreasedInvestigations35/10939/108
ProteinuriaRenal and urinary disorders36/10929/108
White blood cell count decreasedInvestigations24/10931/108
AnaemiaBlood and lymphatic system disorders27/10928/108
Gamma-glutamyltransferase increasedInvestigations17/10928/108
Weight increasedInvestigations27/10921/108

Baseline characteristics

Age, Continuous
Age, Continuous(years)SHR-1210 Q2WSHR-1210 Q3WTotal
Median48.0 (25 to 80)49.5 (23 to 76)49.0 (23 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)SHR-1210 Q2WSHR-1210 Q3WTotal
Female111021
Male9898196
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)SHR-1210 Q2WSHR-1210 Q3WTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)SHR-1210 Q2WSHR-1210 Q3WTotal
China109108217
08

Study locations

17 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233004, China
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Cancer Hospital Chinese Academy of Medical Science
    Beijing, Beijing 100021, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Guangdong General Hospital
    Guangzhou, Guangdong 510080, China
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 515041, China
  • Haerbin Medical University Cancer Hospital
    Haerbin, Heilongjiang 150040, China
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • 81 Hospital Nanjing
    Nanjing, Jiangsu 210002, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130012, China
  • Zhangshan Hospital Fudan University
    Shanghai, Shanghai 200032, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710061, China
  • West China Hospital
    Chengdu, Sichuan 610041, China
  • The First Affiliated Hospital Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
09

References and documents

Publications

  • Shi J, Liu J, Tu X, Li B, Tong Z, Wang T, Zheng Y, Shi H, Zeng X, Chen W, Yin W, Fang W. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. J Immunother Cancer. 2022 Jan;10(1):e003133. doi: 10.1136/jitc-2021-003133. PubMed 35101942 ↗
  • Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Chen C, Zou J. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020 Apr;21(4):571-580. doi: 10.1016/S1470-2045(20)30011-5. Epub 2020 Feb 26. PubMed 32112738 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2020, 39 months.

Results were first posted in Mar 2024, 4 years after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 39 months is close to that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2016
First posted
Dec 12, 2016
StartActual
Nov 15, 2016
Primary completionActual
Mar 3, 2020
CompletionActual
Mar 3, 2020
Results first posted
Mar 15, 2024
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02989922
Responsible party
Sponsor
First posted
Dec 12, 2016
Start date
Nov 15, 2016
Primary completion
Mar 3, 2020
Completion
Mar 3, 2020
Results posted
Mar 15, 2024
Last update
Mar 15, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion